2006;48:438 45. 435. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. 436. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moder- ate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495 504. Erratum in: N Engl J Med. 2006;354:778. 437. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001 9. 438. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383 9. 439. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a de- layed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307 16. 440. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711 8. 441. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm256581. htm. Accessed May 18, 2012. 442. Giraldez RR, Giugliano RP, Mohanavelu S, et al. Baseline low-density li- poprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin orAtorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarc- tion 22) analysis. J Am Coll Cardiol. 2008;52:914 20. 443. Lee KH, Jeong MH, Kim HM, et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low- density lipoprotein cholesterol. 